1 day-0.21%
Current year+3.10%
Current year 4.48
Extreme 4.48
4.68
1 year 4
Extreme 4.0001
5.55
3 years 2.22
Extreme 2.215
6.3
5 years 2.22
Extreme 2.215
50.09
10 years 2.22
Extreme 2.215
151.8
Manager TitleAgeSince
Chief Executive Officer 56 27/03/2023
Chief Tech/Sci/R&D Officer 60 -
Chief Operating Officer 61 30/06/2021
Director TitleAgeSince
Chairman 76 31/07/2015
Director/Board Member 58 31/07/2015
Director/Board Member 69 21/06/2022
Logo CureVac
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Employees
-
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - CureVac
  1. Stock Market
  2. Stocks
  3. CVAC Stock